Russell Investments Group Ltd. Sells 365,288 Shares of Sanofi (NASDAQ:SNY)

Russell Investments Group Ltd. decreased its stake in Sanofi (NASDAQ:SNY - Free Report) by 48.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 383,677 shares of the company's stock after selling 365,288 shares during the period. Russell Investments Group Ltd.'s holdings in Sanofi were worth $18,505,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Synergy Asset Management LLC acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. boosted its stake in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after buying an additional 543 shares in the last quarter. Lee Danner & Bass Inc. bought a new stake in Sanofi in the 4th quarter valued at $31,000. Sunbelt Securities Inc. raised its stake in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after buying an additional 313 shares in the last quarter. Finally, Sierra Ocean LLC bought a new position in shares of Sanofi during the 4th quarter worth about $44,000. Institutional investors own 14.04% of the company's stock.

Sanofi Price Performance

Shares of NASDAQ SNY traded down $0.46 during mid-day trading on Tuesday, hitting $51.38. 1,817,261 shares of the stock were exchanged, compared to its average volume of 2,326,631. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The stock's fifty day simple moving average is $54.94 and its two-hundred day simple moving average is $52.31. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $129.80 billion, a P/E ratio of 20.67, a PEG ratio of 1.01 and a beta of 0.57.

Remove Ads

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on SNY. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.